Last reviewed · How we verify
Lanzol
At a glance
| Generic name | Lanzol |
|---|---|
| Also known as | lansoprazole |
| Sponsor | Zahra Vahdat Shariatpanahi |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Endoscopic Fundoplication Versus Proton Pump Inhibitors for GERD Treatment (PHASE3)
- Comparison of Daily Single Dose Triple and Conventional Triple Therapies for Helicobacter Pylori Infection (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lanzol CI brief — competitive landscape report
- Lanzol updates RSS · CI watch RSS
- Zahra Vahdat Shariatpanahi portfolio CI